{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:30:34Z","timestamp":1791282634846,"version":"4.1.0"},"reference-count":68,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Arguably, one of the most common and consequential laboratory tests performed in the world is\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    susceptibility testing.\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    resistance is defined by growth of \u22651% of a bacillary inoculum on the critical concentration of an antibiotic. The critical concentration was chosen based on inhibition of \u226595% of wild-type isolates. The critical concentration of isoniazid is either 0.2 or 1.0 mg\/liter, that of rifampin is 1.0 mg\/liter, that of pyrazinamide is 100 mg\/liter, that of ethambutol is 5.0 mg\/liter, and that of fluoroquinolones is 1.0 mg\/liter. However, the relevance of these concentrations to microbiologic and clinical outcomes is unclear. Critical concentrations were identified using the ability to achieve the antibiotic area under the concentration-time curve\/MIC ratio associated with \u226590% of maximal kill (EC\n                    <jats:sub>90<\/jats:sub>\n                    ) of\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    in \u226590% of patients. Population pharmacokinetic parameters and their variability encountered in tuberculosis patients were utilized in Monte Carlo simulations to determine the probability that particular daily doses of the drugs would achieve or exceed the EC\n                    <jats:sub>90<\/jats:sub>\n                    in the epithelial lining fluid of 10,000 tuberculosis patients. Failure to achieve EC\n                    <jats:sub>90<\/jats:sub>\n                    in \u226590% of patients at a particular MIC was defined as drug resistance. The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg\/liter was identified for pyrazinamide, 0.0312 mg\/liter and 0.125 mg\/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg\/liter was defined for rifampin. Thus, current critical concentrations of first-line antituberculosis drugs are overoptimistic and should be set lower. With the proposed breakpoints, the rates of multidrug-resistant tuberculosis could become 4-fold higher than currently assumed.\n                  <\/jats:p>","DOI":"10.1128\/aac.01474-09","type":"journal-article","created":{"date-parts":[[2010,1,19]],"date-time":"2010-01-19T23:53:18Z","timestamp":1263945198000},"page":"1484-1491","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":120,"title":["New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic\/Pharmacodynamic Science and Population Pharmacokinetic Variability"],"prefix":"10.1128","volume":"54","author":[{"given":"Tawanda","family":"Gumbo","sequence":"first","affiliation":[{"name":"Department of Medicine, UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"400","volume":"74","year":"1956","unstructured":"Allison, S. T. 1956. Pyrazinamide-isoniazid in low dosage in treatment of pulmonary tuberculosis. Am. Rev. Tuberc.74:400-409.","journal-title":"Am. Rev. Tuberc."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.10.011"},{"key":"e_1_3_2_5_2","unstructured":"Anti-tuberculosis drug resistance in the world. 2009"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/0036554021000026938"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200201-047OC"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1775-1781.2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(69)90017-8"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-360OC"},{"key":"e_1_3_2_12_2","first-page":"565","volume":"29","year":"1963","unstructured":"Canetti, G., S. Froman, J. Grosset, P. Hauduroy, M. Langerova, H. T. Mahler, G. Meissner, D. A. Mitchison, and L. Sula. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. W. H. O.29:565-578.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/595689"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_2_15_2","unstructured":"Susceptibility testing of mycobacteria nocardiae and other aerobic actinomycetes; approved standard. 2003"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60333-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1329"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2891-2896.2001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443060-00003"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2358-2364.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030384"},{"key":"e_1_3_2_22_2","first-page":"1","year":"2007","unstructured":"Craig, W. A. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p.1 -19. In C. H. Nightangle, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and practice. Informa Healthcare USA, Inc., New York, NY.","journal-title":"Antimicrobial pharmacodynamics in theory and practice"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_C.29"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-009-7108-9"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200301000-00008"},{"key":"e_1_3_2_26_2","unstructured":"ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software. 2009"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-06"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"e_1_3_2_29_2","first-page":"1318","volume":"10","year":"2006","unstructured":"Donald, P. R., D. Maher, J. S. Maritz, and S. Qazi. 2006. Ethambutol dosage for the treatment of children: literature review and recommendations. Int. J. Tuberc. Lung Dis.10:1318-1330.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0078OC"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01520-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/424849"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-07"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.4.1498-1501.2000"},{"key":"e_1_3_2_38_2","first-page":"13","year":"1991","unstructured":"Heifets, L. B. 1991. Antituberculosis drugs: antimicrobial activity in vitro, p.13 -57. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL.","journal-title":"Drug susceptibility in the chemotherapy of mycobacterial infections"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2951-2957.2004"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.41823"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1733-1738.2005"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199406000-00003"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00118-09"},{"key":"e_1_3_2_46_2","unstructured":"Anthropometric reference data for children and adults: U.S. population 1999-2002. 2005"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000146"},{"key":"e_1_3_2_48_2","first-page":"423","volume":"133","year":"1986","unstructured":"Mitchison, D. A., and A. J. Nunn. 1986. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis.133:423-430.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_49_2","first-page":"262","volume":"123","year":"1981","unstructured":"Moulding, T. S. 1981. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am. Rev. Respir. Dis.123:262-264.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2473"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.1549"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2949"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01036-07"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2670"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00239-X"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.7.1002"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"e_1_3_2_58_2","unstructured":"Meningeal tuberculosis has very poor long term mortality despite standard therapy."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061728"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4809(72)90071-7"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00201-7"},{"key":"e_1_3_2_62_2","unstructured":"J. Infect. Dis."},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-06"},{"key":"e_1_3_2_64_2","first-page":"65","volume":"14","year":"2010","unstructured":"Wang, J. Y., J. T. Wang, T. H. Tsai, C. L. Hsu, C. J. Yu, P. R. Hsueh, L. N. Lee, and P. C. Yang. 2010. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.14:65-71.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0141-z"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-07"},{"key":"e_1_3_2_67_2","first-page":"754","volume":"47","year":"1999","unstructured":"Yamane, N., S. Ichiyama, S. Kawahara, Y. Iinuma, H. Saitoh, M. Shimojima, H. Udagawa, and I. Nakasone. 1999. Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis\u2014evaluation of interlaboratory precision and interpretive compatibility with agar proportion method. Jpn. J. Clin. Pathol.47:754-766.","journal-title":"Jpn. J. Clin. Pathol."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-51-1-42"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf214"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01474-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01474-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:21:23Z","timestamp":1645456883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01474-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1128\/AAC.01474-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.01474-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"2009-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}